3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1
3
Phase NA
2
Phase 4
2
Phase EARLY_PHASE1
1
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Dermatologic
1
Conditions
Nasopharyngeal Carcinoma
3
Esophageal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Spinocerebellar Degenerations
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Nasopharyngeal Cancinoma (NPC)
1
Melanoma
1
Esophageal Squamous Cell Carcinoma
1
Carcinoma, Hepatocellular
1
Anus Neoplasms
1
Anal Canal Carcinoma
1
Interventions
Dacarbazine
25
Nivolumab
24
pembrolizumab
19
Ipilimumab
18
Interferon-alpha
10
trametinib
8
Vemurafenib
8
dabrafenib
7
aldesleukin
7
Temozolomide
7
Introns
7
Interferon alpha-2
6
Interleukin-2
5
Cisplatin
5
Chemotherapy, Adjuvant
5
talimogene laherparepvec
4
cemiplimab
4
binimetinib
4
Radiotherapy
4
Paclitaxel
4
Granulocyte-Macrophage Colony-Stimulating Factor
4
sargramostim
3
encorafenib
3
cobimetinib
3
Vinblastine
3
Surgical Procedures, Operative
3
Specimen Handling
3
Sodium Chloride
3
Radiosurgery
3
Opdualag
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Melanoma
×
Immune Checkpoint Inhibitors
×
Clear all
NCT05522660
2026-04-27
USZ-STRIKE
ETOP IBCSG Partners Foundation
Phase 3
Recruiting
180 enrolled